Careers  |  Sign In  |  Register  |   Twitter

Reuters Health • The Doctor's Channel Daily Newscast

Breast Cancer Recurrence Higher with Intraoperative Radiotherapy than External RT

NEW YORK (Reuters Health) – Results of a randomized trial conducted in Italy indicate that conventional external radiotherapy (RT) after breast conserving surgery for early breast cancer is more effective than intraoperative radiotherapy in controlling disease recurrence. Nonetheless, “Overall survival...

Reuters Health • The Doctor's Channel Daily Newscast

Tolvaptan Corrects Hyponatremia in Cancer Patients

NEW YORK (Reuters Health) – In hospitalized cancer patients, the common problem of hyponatremia can be corrected by administration of the orally active V2 receptor antagonist, tolvaptan. The finding comes from a relatively small double-blind placebo-controlled trial.  “The correction in the tolvaptan...

Reuters Health • The Doctor's Channel Daily Newscast

TNF Opens Blood-Brain Barrier at Brain Metastasis Sites

By Will Boggs, MD NEW YORK (Reuters Health) –In mice, treatment with tumor necrosis factor (TNF) or lymphotoxin makes the blood-brain barrier (BBB) selectively permeable at metastasis sites, researchers from the UK report. “That brain metastasis, which is usually a death sentence for the individual...

Reuters Health • The Doctor's Channel Daily Newscast

Chemotherapy Has Not Improved Median Survival with Metastatic Gastric Cancer

By Will Boggs, MD NEW YORK (Reuters Health) – Median survival of patients with metastatic gastric cancer has not improved, despite increased use of chemotherapy, researchers from The Netherlands report. “Despite the increased prescription of palliative chemotherapy and the presumed stage migration, the...
By Will Boggs, MD NEW YORK (Reuters Health) – Improved survival among women with stage I or II endometrial cancer who undergo radiotherapy and lymphadenectomy may be attributable in large part to selective application of these therapies in healthier patients, according to a new analysis of SEER...

Reuters Health • The Doctor's Channel Daily Newscast

Some Patients with GI Stromal Tumors May Benefit from Resumption of Imatinib

By Will Boggs, MD NEW YORK (Reuters Health) – Some patients with gastrointestinal stromal tumors (GIST) may benefit from resuming imatinib even after a previous failure of imatinib and sunitinib, according to results from the RIGHT trial. “Contrary to prior oncology principle, reintroduction of treatment...

Reuters Health • The Doctor's Channel Daily Newscast

Breast Cancer Metastases Can Have Different Receptor Profiles

NEW YORK (Reuters Health) – Breast cancer metastases in a given patient often have a different receptor status, a new study demonstrates. “Different metastases within the same patient may have different receptor profiles, which may explain the lack of response to endocrine treatment we so often...

Reuters Health • The Doctor's Channel Daily Newscast

Few Cancer Screening Trials Quantify Harm from Screening

NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare decision makers, healthcare practitioners, and, ultimately, patients therefore cannot make informed choices about cancer...

Reuters Health • The Doctor's Channel Daily Newscast

Adjuvant Chemotherapy Helpful for Stage III Mucinous Colorectal Cancer

NEW YORK (Reuters Health) – A Dutch population-based study has shown that, while mucinous colorectal cancer is thought to carry a poor prognosis, it actually responds as well to adjuvant chemotherapy as nonmucinous CRC. “Therefore, current adjuvant treatment recommendations should not take histology into...
NEW YORK (Reuters Health) – Ten-year follow-up data from two UK trials confirm that a lower total dose of radiotherapy delivered in fewer, larger fractions is at least as safe and effective as the historical standard RT regimen for treating early breast cancer after primary surgery. “The results support...